Decision Making Deficit and DNA Methylation in Opioid Receptor Genes Among Community Heroin Addicts

Heroin Addiction Clinical Trial

Official title:

Decision Making Deficit and DNA Methylation in Opioid Receptor Genes Among Community Heroin Addicts

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT01668732
• Other study ID #: MD101SCW01
• Status: Not yet recruiting
• Phase: N/A
• First received: August 16, 2012
• Last updated: August 17, 2012
• Start date: August 2012
• Est. completion date: July 2015

Study information

• Verified date: August 2012
• Source: National Health Research Institutes, Taiwan
• Contact: Sheng Chang Wang, M.D., M.Sc.
• Phone: 886-37-246166
• Email: scwang69[@]gmail.com
• Is FDA regulated: No
• Health authority: Taiwan: National Health Research Institutes
• Study type: Observational

Clinical Trial Summary

Heroin addiction has emerged as a serious problem with tremendous impacts on the addicts and the society. Since the introduction of opioids substitutive treatment in 2006, more than 30,000 heroin addicts had received treatment, and nearly 12,000 continued on treatment currently. However, an unknown proportion of patients hidden in community remained un-treatment. To motivate the community heroin addicts is thus a challenging task.

It is suggested that decision making deficit is core feature which determine outcomes and treatment motivations in patients with addiction disorders. Recently, the state-of-the-art development of epigenetics uncover that environmental modification, via altering level of DNA methylation and gene expression will influence on neurocognitive functioning.

Via respondent-driven sampling, this study aims to recruit a representative sample targeting at the hard-to-reach community heroin addicts. The goal of this study is to identify the clinical feature as well as decision making-related neurocognitive deficit in these patients. Moreover, the investigators will explore the interplay of clinical features, DNA methylation and gene expressions on opioids receptor genes. The findings will help to clarify the clinical characteristics of community heroin addicts, to uncover the links between DNA methylation and clinical features of heroin addiction and to develop modifiable treatment targets in the future.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 1
• Est. completion date: July 2015
• Est. primary completion date: July 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 20 Years to 65 Years

Eligibility

Inclusion Criteria:

• 1) 20 to 65 of age; 2) meeting DSM-IV criteria of opioids dependence

Exclusion Criteria:

Study Design

Observational Model: Case-Only, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Heroin Addiction
• Heroin Dependence

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
National Health Research Institutes, Taiwan